Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase II
Rachael E. Hawtin, David E. Stockett, Jo Ann W. Byl et al. · 2010
Read Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase II by Rachael E. Hawtin, David E. Stockett, Jo Ann W. Byl et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0010186.txt.
Description
The authors were Rachael Hawtin, David Stockett, Jo Ann Byl, and others. Their 2010 PLOS ONE study described a cancer drug candidate called voreloxin. It targets topoisomerase II, an enzyme vital for copying DNA and sorting chromosomes. Existing drugs on that target work, but tumors often resist them and side effects limit their use in patients.
Voreloxin is a quinolone derivative that slips into DNA and poisons the target enzyme. A new chemical family on a proven target may dodge some known resistance routes. The paper lays out how the drug acts, a step toward clinical testing.
Catalog record
| CREATOR | Rachael E. Hawtin, David E. Stockett, Jo Ann W. Byl et al. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0010186